Moreover, as anti-EGFR therapy with cetuximab and panitumumab is approved for wild-type RAS mCRC and KRAS and BRAF are considered effective predictors of anti-EGFR therapy [35,36], ctDNA detection could represent an alternative tool for the selection of anti-EGFR treatment due to its correlation with RAS mutational status of tumor tissue [37]. Here, BRAF is linked to neoplasm.